RBC Capital Reiterates Outperform on Boston Scientific, Maintains $115 Price Target

RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Boston Scientific (NYSE: BSX) and maintained a price target of $115 for the stock. This endorsement reflects confidence in the company's performance and market position.